Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Swedbank AB

Swedbank AB lowered its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 109,409 shares of the company’s stock after selling 3,101 shares during the quarter. Swedbank AB’s holdings in Teva Pharmaceutical Industries were worth $1,972,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in TEVA. Clal Insurance Enterprises Holdings Ltd raised its holdings in shares of Teva Pharmaceutical Industries by 6.8% during the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock valued at $621,337,000 after acquiring an additional 2,204,623 shares during the last quarter. National Pension Service increased its holdings in shares of Teva Pharmaceutical Industries by 107.3% in the third quarter. National Pension Service now owns 3,170,640 shares of the company’s stock valued at $57,135,000 after purchasing an additional 1,640,940 shares during the last quarter. Driehaus Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at approximately $23,115,000. Davidson Kempner Capital Management LP increased its holdings in shares of Teva Pharmaceutical Industries by 152.5% in the second quarter. Davidson Kempner Capital Management LP now owns 1,765,485 shares of the company’s stock valued at $28,689,000 after purchasing an additional 1,066,150 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Teva Pharmaceutical Industries by 13.4% in the second quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock valued at $141,839,000 after purchasing an additional 1,031,400 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on TEVA. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Barclays increased their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Finally, UBS Group increased their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Trading Down 0.1 %

TEVA opened at $16.57 on Thursday. Teva Pharmaceutical Industries Limited has a 52 week low of $9.35 and a 52 week high of $19.31. The business has a fifty day simple moving average of $17.60 and a 200-day simple moving average of $17.35. The firm has a market cap of $18.77 billion, a P/E ratio of -19.49, a P/E/G ratio of 1.30 and a beta of 0.87. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57.

Insider Transactions at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.55% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.